Historical Valuation
Day One Biopharmaceuticals Inc (DAWN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.25 is considered Undervalued compared with the five-year average of -8.34. The fair price of Day One Biopharmaceuticals Inc (DAWN) is between 31.44 to 36.35 according to relative valuation methord. Compared to the current price of 8.94 USD , Day One Biopharmaceuticals Inc is Undervalued By 71.57%.
Relative Value
Fair Zone
31.44-36.35
Current Price：8.94
71.57%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Day One Biopharmaceuticals Inc (DAWN) has a current Price-to-Book (P/B) ratio of 2.02. Compared to its 3-year average P/B ratio of 2.90 , the current P/B ratio is approximately -30.62% higher. Relative to its 5-year average P/B ratio of 3.13, the current P/B ratio is about -35.57% higher. Day One Biopharmaceuticals Inc (DAWN) has a Forward Free Cash Flow (FCF) yield of approximately -13.36%. Compared to its 3-year average FCF yield of -11.28%, the current FCF yield is approximately 18.40% lower. Relative to its 5-year average FCF yield of -9.13% , the current FCF yield is about 46.21% lower.
P/B
Median3y
2.90
Median5y
3.13
FCF Yield
Median3y
-11.28
Median5y
-9.13
Competitors Valuation Multiple
AI Analysis for DAWN
The average P/S ratio for DAWN competitors is 53.78, providing a benchmark for relative valuation. Day One Biopharmaceuticals Inc Corp (DAWN.O) exhibits a P/S ratio of 4.25, which is -92.1% above the industry average. Given its robust revenue growth of -57.56%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for DAWN
1Y
3Y
5Y
Market capitalization of DAWN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of DAWN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is DAWN currently overvalued or undervalued?
Day One Biopharmaceuticals Inc (DAWN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.25 is considered Undervalued compared with the five-year average of -8.34. The fair price of Day One Biopharmaceuticals Inc (DAWN) is between 31.44 to 36.35 according to relative valuation methord. Compared to the current price of 8.94 USD , Day One Biopharmaceuticals Inc is Undervalued By 71.57% .
What is Day One Biopharmaceuticals Inc (DAWN) fair value?
DAWN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Day One Biopharmaceuticals Inc (DAWN) is between 31.44 to 36.35 according to relative valuation methord.
How does DAWN's valuation metrics compare to the industry average?
The average P/S ratio for DAWN's competitors is 53.78, providing a benchmark for relative valuation. Day One Biopharmaceuticals Inc Corp (DAWN) exhibits a P/S ratio of 4.25, which is -92.10% above the industry average. Given its robust revenue growth of -57.56%, this premium appears unsustainable.
What is the current P/B ratio for Day One Biopharmaceuticals Inc (DAWN) as of Jan 10 2026?
As of Jan 10 2026, Day One Biopharmaceuticals Inc (DAWN) has a P/B ratio of 2.02. This indicates that the market values DAWN at 2.02 times its book value.
What is the current FCF Yield for Day One Biopharmaceuticals Inc (DAWN) as of Jan 10 2026?
As of Jan 10 2026, Day One Biopharmaceuticals Inc (DAWN) has a FCF Yield of -13.36%. This means that for every dollar of Day One Biopharmaceuticals Inc’s market capitalization, the company generates -13.36 cents in free cash flow.
What is the current Forward P/E ratio for Day One Biopharmaceuticals Inc (DAWN) as of Jan 10 2026?
As of Jan 10 2026, Day One Biopharmaceuticals Inc (DAWN) has a Forward P/E ratio of -14.73. This means the market is willing to pay $-14.73 for every dollar of Day One Biopharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Day One Biopharmaceuticals Inc (DAWN) as of Jan 10 2026?
As of Jan 10 2026, Day One Biopharmaceuticals Inc (DAWN) has a Forward P/S ratio of 4.25. This means the market is valuing DAWN at $4.25 for every dollar of expected revenue over the next 12 months.